Mainz Biomed enhances PancAlert using AI for biomarker selection

Mainz Biomed has expanded its collaboration with Liquid Biosciences to enhance biomarker selection for its PancAlert pancreatic cancer detection test using AI technology. The first phase showed promising results, leading to plans for a second phase that includes microbiome biomarkers. Pancreatic cancer has a global mortality rate of approximately 466,000 annually, with a 5-year survival rate of about 11% in the U.S.